361 related articles for article (PubMed ID: 23541016)
1. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
[TBL] [Abstract][Full Text] [Related]
2. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
4. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
5. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
Favia G; Pilolli GP; Maiorano E
J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
[TBL] [Abstract][Full Text] [Related]
7. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
[TBL] [Abstract][Full Text] [Related]
9. Review of current literature and implications of RANKL inhibitors for oral health care providers.
Epstein MS; Ephros HD; Epstein JB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
[TBL] [Abstract][Full Text] [Related]
10. Antiresorptives and osteonecrosis of the jaw.
Yamashita J; McCauley LK
J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
[TBL] [Abstract][Full Text] [Related]
11. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
12. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
[TBL] [Abstract][Full Text] [Related]
15. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.
Kademani D; Koka S; Lacy MQ; Rajkumar SV
Mayo Clin Proc; 2006 Aug; 81(8):1100-3. PubMed ID: 16901034
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
18. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
19. Dental sinus tracts mimicking scrofuloderma: cutaneous presentation of underlying bisphosphonate-related osteonecrosis of the jaw.
Kang HS; Lee JW; Kim JS
Clin Exp Dermatol; 2011 Aug; 36(6):624-7. PubMed ID: 21771007
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw.
Drozdzowska B
Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
